Huiyi Lv
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Huiyi Lv has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Bing-Kun Cai
Department of Pharmacy, The Second Affiliated Hospital of Dalian Medical University, Dalian, China
1 shared publicationDi Wu
Department of Pharmacy, The Second Affiliated Hospital of Dalian Medical University, China
1 shared publication- Di Wu
Department of Pharmacy The 2nd Affiliated Hospital of Dalian Medical University Dalian China
1 shared publication Feihong Dong
Department of Pharmacy, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116023, P.R. China
1 shared publication- Feihong Dong
College of Future Technology, State Key Laboratory of Membrane Biology, Peking-Tsinghua Center for Life Sciences, and Institute of Molecular Medicine, Peking University, Beijing, China
1 shared publication Hang Yin
Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10021, USA
1 shared publication
Latest Publications
- Open Access
- 28 December 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
Effects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction
Sodium-glucose co-transport protein 2 (SGLT2) inhibitors, a novel category of oral hypoglycemic agents, offer a promising outlook for individuals experiencing heart failure with reduced ejection fraction. Evidence is emerging that highlights their potential in alleviating myocardial fibrosis and oxidative stress. However, the precise mechanisms through which SGLT2 inhibitors influence myocardial fibrosis induced by angiotensin II (Ang II) or transforming growth factor-β1 (TGF-β1) are not fully understood. This study aims to explore the intricate mechanisms by which SGLT2 inhibitors ameliorate myocardial fibrosis, particularly focusing on the nuanced interplay within the SIRT6 signaling pathway. Primary cardiac fibroblasts were isolated from the hearts of 1-3-day-old neonatal KM mice, were stimulated with Ang II or TGF-β1 to establish an in vitro model of myocardial fibrosis. Treatment with 10 µM Empagliflozin (EMPA) and Dapagliflozin (DAPA) significantly curtailed the proliferation of cardiac fibroblasts, substantially reduced collagen expression induced by Ang II/TGF-β1, and mitigated the phenotypic transformation and oxidative stress response. SIRT6, which is closely associated with myocardial fibrosis, demonstrated that the suppression its expression attenuated the protective effects of EMPA and DAPA against myocardial fibrosis and oxidative stress. Our findings suggest that SGLT2 inhibitors markedly decrease the Ang II/TGF-β1-induced transformation of cardiac fibroblasts to a myofibroblast phenotype by upregulating SIRT6 protein expression, thereby inhibiting oxidative stress and ameliorating myocardial fibrosis.
- 28 December 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
Open AccessEffects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction
Sodium-glucose co-transport protein 2 (SGLT2) inhibitors, a novel category of oral hypoglycemic agents, offer a promising outlook for individuals experiencing heart failure with reduced ejection fraction. Evidence is emerging that highlights their potential in alleviating myocardial fibrosis and oxidative stress. However, the precise mechanisms through which SGLT2 inhibitors influence myocardial fibrosis induced by angiotensin II (Ang II) or transforming growth factor-β1 (TGF-β1) are not fully understood. This study aims to explore the intricate mechanisms by which SGLT2 inhibitors ameliorate myocardial fibrosis, particularly focusing on the nuanced interplay within the SIRT6 signaling pathway. Primary cardiac fibroblasts were isolated from the hearts of 1-3-day-old neonatal KM mice, were stimulated with Ang II or TGF-β1 to establish an in vitro model of myocardial fibrosis. Treatment with 10 µM Empagliflozin (EMPA) and Dapagliflozin (DAPA) significantly curtailed the proliferation of cardiac fibroblasts, substantially reduced collagen expression induced by Ang II/TGF-β1, and mitigated the phenotypic transformation and oxidative stress response. SIRT6, which is closely associated with myocardial fibrosis, demonstrated that the suppression its expression attenuated the protective effects of EMPA and DAPA against myocardial fibrosis and oxidative stress. Our findings suggest that SGLT2 inhibitors markedly decrease the Ang II/TGF-β1-induced transformation of cardiac fibroblasts to a myofibroblast phenotype by upregulating SIRT6 protein expression, thereby inhibiting oxidative stress and ameliorating myocardial fibrosis.
- Open Access
- 13 December 2024
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 11, 1495640
Clinical impacts of total parenteral nutrition in hematopoietic stem cell transplantation patients with high nutritional risk
Background: Hematopoietic stem cell transplantation (HSCT) patients often receive consecutive intensive chemotherapy, which can lead to gastrointestinal complications and acute graft-versus-host disease (GVHD), placing patients at high nutritional risk.Aim: This retrospective study aimed to evaluate the benefits of nutritional support in maintaining nutritional status, reducing weight loss without increasing the incidence of catheter-related bloodstream infections (CRBSI) or liver dysfunction, and improving clinical outcomes in HSCT patients at high nutritional risk.Methods: A total of 526 patients who underwent HSCT were included in the study. Based on the Nutrition Risk Screening-2002 (NRS-2002) and propensity score matching, 70 patients were assigned to the control group (without parenteral nutrition) and 70 to the enhanced nutrition group (with parenteral nutrition) between 2012 and 2022. We compared data between the two groups at different time points (days 3, 7, 10, and 14 after transplantation and the day before discharge) on the following: (1) effectiveness: weight loss, albumin, and prealbumin levels; (2) safety: incidence of CRBSI and conjugated bilirubin levels; and (3) clinical outcomes: hospital stay duration, rate of rehospitalization, hospitalization costs, and survival rates.Results: Our results showed that total parenteral nutrition (TPN) effectively mitigated weight loss on days 10 and 14 and the day before discharge, while also improving albumin (33.41 ± 4.57 in the control group, 34.87 ± 4.08 in the TPN group, p < 0.05; 33.72 ± 3.52 in the control group, 35.27 ± 4.04 in the TPN group, p < 0.05; 34.09 ± 4.44 in the control group, 35.55 ± 3.87 in the TPN group, p < 0.05) and prealbumin (245.18 ± 79.94 in the control group, 274.26 ± 86.73 in the TPN group, p < 0.05; 233.27 ± 79.57 in the control group, 279.34 ± 80.20 in the TPN group, p < 0.01; 247.24 ± 83.29 in the control group, 280.65 ± 100.22 in the TPN group, p < 0.05) levels during the same periods. In addition, there were no significant differences in CRBSI incidence or liver function between the non-TPN and TPN groups. Furthermore, the TPN group experienced a shorter length of hospital stay (48.06 ± 13.90 in the control group, 42.13 ± 14.22* in the TPN group, p < 0.05) and lower rates of unexpected rehospitalization (37.1% in the control group, 21.4% in the TPN group, p < 0.05).Conclusion: This study demonstrated that effective TPN formulations improved nutritional status, ensured patient safety, and contributed to better clinical outcomes in HSCT patients at high nutritional risk. These findings support the use of nutritional interventions in hematologic malignancy patients receiving induction therapy prior to transplantation.
- 13 December 2024
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 11, 1495640
Open AccessClinical impacts of total parenteral nutrition in hematopoietic stem cell transplantation patients with high nutritional risk
Background: Hematopoietic stem cell transplantation (HSCT) patients often receive consecutive intensive chemotherapy, which can lead to gastrointestinal complications and acute graft-versus-host disease (GVHD), placing patients at high nutritional risk.Aim: This retrospective study aimed to evaluate the benefits of nutritional support in maintaining nutritional status, reducing weight loss without increasing the incidence of catheter-related bloodstream infections (CRBSI) or liver dysfunction, and improving clinical outcomes in HSCT patients at high nutritional risk.Methods: A total of 526 patients who underwent HSCT were included in the study. Based on the Nutrition Risk Screening-2002 (NRS-2002) and propensity score matching, 70 patients were assigned to the control group (without parenteral nutrition) and 70 to the enhanced nutrition group (with parenteral nutrition) between 2012 and 2022. We compared data between the two groups at different time points (days 3, 7, 10, and 14 after transplantation and the day before discharge) on the following: (1) effectiveness: weight loss, albumin, and prealbumin levels; (2) safety: incidence of CRBSI and conjugated bilirubin levels; and (3) clinical outcomes: hospital stay duration, rate of rehospitalization, hospitalization costs, and survival rates.Results: Our results showed that total parenteral nutrition (TPN) effectively mitigated weight loss on days 10 and 14 and the day before discharge, while also improving albumin (33.41 ± 4.57 in the control group, 34.87 ± 4.08 in the TPN group, p < 0.05; 33.72 ± 3.52 in the control group, 35.27 ± 4.04 in the TPN group, p < 0.05; 34.09 ± 4.44 in the control group, 35.55 ± 3.87 in the TPN group, p < 0.05) and prealbumin (245.18 ± 79.94 in the control group, 274.26 ± 86.73 in the TPN group, p < 0.05; 233.27 ± 79.57 in the control group, 279.34 ± 80.20 in the TPN group, p < 0.01; 247.24 ± 83.29 in the control group, 280.65 ± 100.22 in the TPN group, p < 0.05) levels during the same periods. In addition, there were no significant differences in CRBSI incidence or liver function between the non-TPN and TPN groups. Furthermore, the TPN group experienced a shorter length of hospital stay (48.06 ± 13.90 in the control group, 42.13 ± 14.22* in the TPN group, p < 0.05) and lower rates of unexpected rehospitalization (37.1% in the control group, 21.4% in the TPN group, p < 0.05).Conclusion: This study demonstrated that effective TPN formulations improved nutritional status, ensured patient safety, and contributed to better clinical outcomes in HSCT patients at high nutritional risk. These findings support the use of nutritional interventions in hematologic malignancy patients receiving induction therapy prior to transplantation.
- Open Access
- 24 September 2024
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 30 (6) , 1-13
Exploring the anti‑oxidative mechanisms of Rhodiola rosea in ameliorating myocardial fibrosis through network pharmacology and in vitro experiments
Myocardial fibrosis (MF) significantly compromises cardiovascular health by affecting cardiac function through excessive collagen deposition. This impairs myocardial contraction and relaxation and leads to severe complications and increased mortality. The present study employed network pharmacology and in vitro assays to investigate the bioactive compounds of Rhodiola rosea and their targets. Using databases such as HERB, the Encyclopedia of Traditional Chinese Medicine, Pubchem, OMIM and GeneCards, the present study identified effective components and MF‑related targets. Network analysis was conducted with Cytoscape to develop a Drug‑Ingredient‑Target‑Disease network and the STRING database was utilized to construct a protein‑protein interaction network. Key nodes were analyzed for pathway enrichment using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes. Molecular interactions were further explored through molecular docking techniques. The bioactivity of salidroside (SAL), the principal component of Rhodiola rosea, against MF was experimentally validated in H9c2 cardiomyocytes treated with angiotensin II and assessed for cell viability, protein expression and oxidative stress markers. Network pharmacology identified 25 active ingredients and 372 targets in Rhodiola rosea, linking SAL with pathways such as MAPK, EGFR, advanced glycosylation end products‑advanced glycosylation end products receptor and Forkhead box O. SAL showed significant interactions with core targets such as albumin, IL6, AKT serine/threonine kinase 1, MMP9 and caspase‑3. In vitro, SAL mitigated AngII‑induced increases in collagen I and alpha smooth muscle actin protein levels and oxidative stress markers, demonstrating dose‑dependent effectiveness in reversing MF. SAL from Rhodiola rosea exhibited potent anti‑oxidative properties that mitigated MF by modulating multiple molecular targets and signaling pathways. The present study underscored the therapeutic potential of SAL in treating oxidative stress‑related cardiovascular diseases.
- 24 September 2024
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 30 (6) , 1-13
Open AccessExploring the anti‑oxidative mechanisms of Rhodiola rosea in ameliorating myocardial fibrosis through network pharmacology and in vitro experiments
Myocardial fibrosis (MF) significantly compromises cardiovascular health by affecting cardiac function through excessive collagen deposition. This impairs myocardial contraction and relaxation and leads to severe complications and increased mortality. The present study employed network pharmacology and in vitro assays to investigate the bioactive compounds of Rhodiola rosea and their targets. Using databases such as HERB, the Encyclopedia of Traditional Chinese Medicine, Pubchem, OMIM and GeneCards, the present study identified effective components and MF‑related targets. Network analysis was conducted with Cytoscape to develop a Drug‑Ingredient‑Target‑Disease network and the STRING database was utilized to construct a protein‑protein interaction network. Key nodes were analyzed for pathway enrichment using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes. Molecular interactions were further explored through molecular docking techniques. The bioactivity of salidroside (SAL), the principal component of Rhodiola rosea, against MF was experimentally validated in H9c2 cardiomyocytes treated with angiotensin II and assessed for cell viability, protein expression and oxidative stress markers. Network pharmacology identified 25 active ingredients and 372 targets in Rhodiola rosea, linking SAL with pathways such as MAPK, EGFR, advanced glycosylation end products‑advanced glycosylation end products receptor and Forkhead box O. SAL showed significant interactions with core targets such as albumin, IL6, AKT serine/threonine kinase 1, MMP9 and caspase‑3. In vitro, SAL mitigated AngII‑induced increases in collagen I and alpha smooth muscle actin protein levels and oxidative stress markers, demonstrating dose‑dependent effectiveness in reversing MF. SAL from Rhodiola rosea exhibited potent anti‑oxidative properties that mitigated MF by modulating multiple molecular targets and signaling pathways. The present study underscored the therapeutic potential of SAL in treating oxidative stress‑related cardiovascular diseases.